US · Healthcare · Biotechnology
EPS came in at -0.95 against a street estimate of -0.74 — a miss of 28.4%.
Analysts rate First Tracks Biotherapeutics a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $72.50.
| Fund | Stake |
|---|---|
| EcoR1 Capital, LLC | 8.88% |
| TCG Crossover Management, LLC | 8.10% |
| FMR Inc | 5.75% |
| Affinity Asset Advisors, LLC | 5.69% |
| BlackRock Inc | 5.50% |
| Trails Edge Capital Partners, LP | 4.24% |
| State Street Corp | 4.23% |
| Vanguard Capital Management, LLC | 4.06% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • First Tracks Biotherapeutics (Nasdaq: TRAX) announced positive topline data from the first Phase 1b cohort of ANB033 in celiac dis | 2026-10-13 |
| Quarterly report · Q2 2026 FIRST TRACKS BIOTHERAPEUTICS, INC. — 10-Q SUMMARY FOR Q2 2026 HEADLINE NUMBERS • Cash position: $168.0 million as of June 30, 2026 (down from $238.2 | 2026-08-12 |
| Results announced · Q3 2026 FIRST TRACKS BIOTHERAPEUTICS Q2 2026 SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $168.0 million as of June 30, 2026 • Net loss for six mon | 2026-08-12 |
| Material agreement · Q2 2026 FIRST TRACKS BIOTHERAPEUTICS, INC. – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company entered into a Sublease Agreement on June 15, 2026 with Ana | 2026-06-22 |
| Quarterly report · Q1 2026 FIRST TRACKS BIOTHERAPEUTICS, INC. – 10-Q SUMMARY Q1 2026 (Three Months Ended March 31, 2026) --- HEADLINE NUMBERS • Cash and equivalents: $248.5 m | 2026-05-14 |
| Results announced · Q2 2026 FIRST TRACKS BIOTHERAPEUTICS Q1 2026 SUMMARY HEADLINE NUMBERS • Company launched April 20, 2026 as spin-off from AnaptysBio with $180 million in cas | 2026-05-14 |
| Material agreement · Q2 2026 FIRST TRACKS BIOTHERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company spun off from AnaptysBio on April 20, 2026 • Received $100.0 million in | 2026-04-20 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for First Tracks Biotherapeutics — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.